Skip to main content
. 2013 Aug 22;8(8):e70890. doi: 10.1371/journal.pone.0070890

Figure 1. Design of clinical trial and immunoreactivity for Wnt-5a.

Figure 1

A. Flow chart defining patients enrolled in clinical trial. B–E. Immunoreactivity for Wnt-5a protein in representative sections of invasive breast carcinomas. B. Tumor with strong (+++) Wnt-5a staining, C. Moderate (++) staining for Wnt-5a, D. Weak (+) staining for Wnt-5a, and E. No (−) Wnt-5a expression (left hand panels: 10× magnification; right hand panels: 40×).